By Barbara Obstoj-Cardwell. Editor
Licensing and M&A deals featured in last week’s news. First up, MacroGenics signed a collaboration with US biotech major Gilead Sciences last Monday relating to its antibody MGD024 for indications including myeloid leukemia that could earn the company as much as $1.7 billion. Jazz Pharmaceuticals entered a deal with Zymeworks that could cost it over $1.7 billion for rights to the latter’s zanidatamab, an HER2-targeting antibody. Swiss pharma giant Roche signed a license agreement with Austria’s Hookipa Pharma for HB-7001, an arenaviral immunotherapy for KRAS-mutated cancers. Also, Eli Lilly on Tuesday announced it is acquiring US precision medicines company Akouos for up to $610 million, along with its hearing loss treatment candidate AK-OTOF. And AbbVie announced an agreement to acquire UK biotech DJS Antibodies for around $255 million
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze